title: Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study.
abstract: BACKGROUND
  The objective of this retrospective study was to describe the short- and long-term patterns of IVIg use, safety, and response to treatment in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
  
  
  METHODS
  Response to therapy was defined as an improvement of ≥ 1 point on the modified Rankin score at short- and mid-term visits. Patient status at long term was classified as remission, stability, or non-responder.
  
  
  RESULTS
  Eighty-six patients were included; 60.5% responded at short term and 54.6% at mid-term. At long term, 25.6% of patients were in remission, 65.1% were stable, and 9.3% were non-responders. The only variable associated with remission was a better response during the first 6 months of follow-up.
  
  
  CONCLUSIONS
  A significant percentage of patients did not require any additional drugs in the long term. This suggests that treatment effect or disease outcome may be stable over time, and treatment regimens should therefore be individualized to avoid overtreatment.
authors.affiliation: Neuromuscular Diseases Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08041, Barcelona, Spain; Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Querol
authors.forename: Ricard
authors.initials: R
authors.lastname: Rojas-Garcia
authors.forename: Carlos
authors.initials: C
authors.lastname: Casasnovas
authors.forename: Maria Jose
authors.initials: MJ
authors.lastname: Sedano
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Muñoz-Blanco
authors.forename: Maria Antonia
authors.initials: MA
authors.lastname: Alberti
authors.forename: Carmen
authors.initials: C
authors.lastname: Paradas
authors.forename: Teresa
authors.initials: T
authors.lastname: Sevilla
authors.forename: Julio
authors.initials: J
authors.lastname: Pardo
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Capablo
authors.forename: Rafael
authors.initials: R
authors.lastname: Sivera
authors.forename: Antonio
authors.initials: A
authors.lastname: Guerrero
authors.forename: Eduardo
authors.initials: E
authors.lastname: Gutierrez-Rivas
authors.forename: Isabel
authors.initials: I
authors.lastname: Illa
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000328:Adult; D000368:Aged; D004185:Disability Evaluation; D004558:Electric Stimulation; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000503:physiopathology / Q000628:therapy*; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors
keywords: CIDP; IVIg; effectiveness; long-term; remission